Search

Regeneron Gets US Patent for Radiolabeled Anti-MET Antibodies

The USPTO granted Regeneron Pharmaceuticals, Inc. Patent US12605473B2 covering radiolabeled anti-MET antibodies and MET×MET bispecific antibodies for immuno-PET imaging. The patent includes 28 claims and covers methods of detecting MET proteins in subjects or samples and methods of monitoring treatment efficacy in MET-expressing tumors. The patent application was filed December 29, 2023.